Cat No.
CEI-0275
Description
SNS-032 (BMS-387032) can inhibit CDK2, CDK7 and CDK9 with IC50 of 38 nM, 62 nM and 4 nM.
CAS No.
345627-80-7
Targets
CDK2, CDK7, CDK9
Chemical Name
N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)piperidine-4-carboxamide
M.Wt
380.53
Purity
>99%
Solubility
DMSO 76 mg/mL Water
Storage
2 years at -20centigrade Powder
In vitro
SNS-032 (BMS-387032) is a potent selective inhibitor of cyclin-dependent kinases 2, 7, and 9, and inhibits both transcription and cell cycle. SNS-032 also prevents in vitro angiogenesis, and this action is attributable to blocking of VEGF. Researchers tested cell lines including human umbilical vein endothelial cells (HUVECs) and human glioblastoma cells (U87MG) with SNS-032, and found that SNS-032 can inhibit tumor cell lines proliferation. SNS-032 inhibited threedimensional capillary network formations of endothelial cells. SNS-032 significantly prevented the production of vascular endothelial growth factor (VEGF) in both cell lines, whereas SNS-032 was less effective in preventing capillary network formation and migration of endothelial cells. Inhibitors of cyclin-dependent kinases (Cdks) have been reported to have activities in chronic lymphocytic leukemia cells by inhibiting Cdk7 and Cdk9,SNS-032, which exhibits potent and selective inhibitory activity against Cdk2, Cdk7, and Cdk9, SNS-032 decrease antiapoptotic proteins, resulting in cell death.
